Drug Trial Radar · NCT04997902
Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
45
Actual
Start
Dec 7, 2021
Primary completion
Aug 29, 2025
Study completion Aug 29, 2025
Sponsor
- Lead sponsor
- Kura Oncology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 10, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase 1/2 combination trial of tipifarnib, a farnesyltransferase inhibitor, and alpelisib, a PI3K inhibitor in participants with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) whose tumors overexpress the HRAS protein and/or are PIK3CA-mutated and/or PIK3CA-amplified.
Conditions
- HNSCC
Interventions
TipifarnibDrug
Oral administration
AlpelisibDrug
Oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicity (DLT)Time frame: First 28 days (1 cycle) of combination therapy
- Descriptive statistics of Adverse Events (AEs)Time frame: From Cycle 1 Day 1 until 30 days after last trial intervention dose or 30 days after trial completion, whichever comes first, assessed up to 2 years
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
City of Hope Comprehensive Cancer Center
Duarte, California
Lake Nona DDU (Florida Cancer Specialists)
Orlando, Florida
University of Maryland School of Medicine (Marlene and Stewart Greenebaum Comprehensive Cancer Center)
Baltimore, Maryland
Johns Hopkins University School of Medicine (Sidney Kimmel Comprehensive Cancer Center)
Baltimore, Maryland
Dana-Farber Cancer Institute (Head and Neck Cancer Treatment Center)
Boston, Massachusetts
Washington University, School of Medicine
St Louis, Missouri
Memorial Sloan Kettering Cancer Center
New York, New York
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
UT Southwestern Medical Center (Harold C. Simmons Comprehensive Cancer Center)
Dallas, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.